Bronchoscopic microsampling is a useful complementary diagnostic tool for detecting lung cancer

Area of Science:

• Pulmonology
• Oncology
• Molecular Diagnostics

Background:

• Lung cancer diagnosis relies on detecting genetic and epigenetic alterations.
• Bronchoscopic microsampling (BMS) is a novel technique for obtaining lung epithelial lining fluid (ELF).
• Early detection of lung cancer improves patient outcomes and treatment efficacy.

Purpose of the Study:

• To evaluate the suitability of ELF obtained via BMS for analyzing lung cancer-specific molecular changes.
• To compare the diagnostic sensitivity of ELF with serum and tumor tissue for detecting DNA hypermethylation and gene mutations.
• To assess the potential of BMS as a complementary diagnostic tool for lung cancer.

Main Methods:

• ELF was collected from 61 lung cancer patients using BMS.
• Nucleic acids were purified from ELF, serum, and tumor tissue.
• DNA hypermethylation of tumor suppressor genes (TSGs), EGFR mutations, and EML4-ALK rearrangements were analyzed using methylation-specific PCR and other molecular techniques.

Main Results:

• BMS demonstrated higher sensitivity for detecting DNA hypermethylation in ELF (74.1%) compared to serum (18.5%).
• Over 60% of patients showed hypermethylation in ELF, including stage I cases.
• ELF analysis showed significantly higher sensitivity for EGFR mutations (58.3%) than serum (8.3%), and an EML4-ALK fusion gene was detected in one patient.

Conclusions:

• BMS is a viable method for obtaining ELF for molecular analysis in lung cancer patients.
• ELF analysis via BMS can detect key genetic and epigenetic alterations specific to lung cancer.
• BMS offers a promising complementary diagnostic approach for early lung cancer detection and treatment selection.